Drug intelligence / Profile preview

NOE-109

Development stage: Unknown
Lead developer: Noema Pharma
Modality: Small Molecules

Overview

NOE-109 is a small molecule inhibitor of metabotropic glutamate receptors 2 and 3 (mGluR2/3) being developed by Noema Pharma, a clinical-stage biotech company focused on central nervous system (CNS) disorders characterized by imbalanced neuronal networks. In-licensed from Roche, it is planned for development in undisclosed CNS indications, with preclinical proof-of-concept work and potential initiation of Phase II testing anticipated around 2022. As an mGluR2/3 antagonist, it modulates glutamatergic signaling implicated in various neurological conditions.[1][2][3][5]

Targets

GRM3 (mGluR3)

Beyond the preview

Go deeper on NOE-109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOE-109.

Explore the full profile